KindredBio Announces Filing of an Investigational New Animal Drug Application for KIND-002
/in Frontpage, Investor, News /by Russell RadefeldKIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs
SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed for severe dermatological diseases in dogs.
News
- Kindred Biosciences Initiates Pivotal Efficacy Study of Tirnovetmab (Interleukin-31) Monoclonal Antibody for Canine Atopic DermatitisDecember 22, 2020 - 8:40 am
- Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel DiseaseDecember 21, 2020 - 8:39 am
- Kindred Biosciences Announces Agreement Granting Elanco Exclusive Global Rights for its Parvovirus Monoclonal AntibodyDecember 11, 2020 - 8:04 am
Events
- Event: Kindred Biosciences to Present at Stifel 2020 Virtual Healthcare ConferenceNovember 11, 2020 - 8:38 am
- Event: Kindred Biosciences to Participate in A.G.P. Virtual Healthcare SymposiumNovember 11, 2020 - 8:37 am
- Event: Kindred Biosciences to Announce Third Quarter 2020 Financial ResultsOctober 28, 2020 - 4:10 pm
$4.72
-0.07 (-1.46%)

|
KindredBio proudly supports
Rabies Free Africa